Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU December 10, 2024
Edison Investment Research publishes Executive interview with Sten R. Sörensen, CEO, Cereno Scientific, on positive topline Phase IIa results October 7, 2024
BioStock has published an article and interview with CEO Sten R. Sörensen on the positive topline results from Cereno Scientific’s Phase IIa trial on CS1 in PAH October 3, 2024
Edison Investment Research increases valuation of Cereno Scientific to 3.9 BSEK or SEK 13.9 SEK/share after positive topline data October 2, 2024
Cereno Scientific announces positive topline results of Phase IIa trial with lead candidate CS1 in Pulmonary Arterial Hypertension September 27, 2024
Neuraptive Therapeutics Announces Presentation of Phase 2 Topline Interim Results for NTX-001 at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting September 21, 2024
